{"id":27294,"date":"2025-04-07T12:53:55","date_gmt":"2025-04-07T12:53:55","guid":{"rendered":"https:\/\/www.neuraxpharm.com\/it\/?page_id=27294"},"modified":"2026-05-06T06:44:57","modified_gmt":"2026-05-06T06:44:57","slug":"disegno-dello-studio","status":"publish","type":"page","link":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\/","title":{"rendered":"Disegno dello studio"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"27294\" class=\"elementor elementor-27294\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-9cbb30c elementor-section-height-min-height elementor-section-items-bottom elementor-section-boxed elementor-section-height-default\" data-id=\"9cbb30c\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[],&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4d8939f\" data-id=\"4d8939f\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-1438f8c elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"1438f8c\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-37efccd\" data-id=\"37efccd\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7a25470 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7a25470\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4337a6d\" data-id=\"4337a6d\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-5e3e272 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"5e3e272\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-e6477be\" data-id=\"e6477be\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ea85dd1 jet-breadcrumbs-align-left elementor-widget elementor-widget-jet-breadcrumbs\" data-id=\"ea85dd1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"jet-breadcrumbs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-jet-breadcrumbs jet-blocks\">\n\t\t<div class=\"jet-breadcrumbs\">\n\t\t<div class=\"jet-breadcrumbs__content\">\n\t\t<div class=\"jet-breadcrumbs__wrap\"><div class=\"jet-breadcrumbs__item\"><a href=\"https:\/\/www.neuraxpharm.com\/it\/\" class=\"jet-breadcrumbs__item-link is-home\" rel=\"home\" title=\"Home\">Home<\/a><\/div>\n\t\t<\/div>\n\t\t<\/div>\n\t\t<\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fe031c5 elementor-widget elementor-widget-text-editor\" data-id=\"fe031c5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>BRIUMVI\u00ae \u00e8 stato valutato in 2 studi clinici identici globali randomizzati ed di FASE<sup>3<\/sup><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-f36cec3 elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"f36cec3\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-d2fcffc\" data-id=\"d2fcffc\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-985236d elementor-widget elementor-widget-text-editor\" data-id=\"985236d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tCriteri di inclusione:\n<ul>\n \t<li>Sclerosi multipla recidivante\n<\/li>\n \t<li>Punteggio EDSS (Expanded Disability Status Scale) 0-5,5\n<\/li>\n \t<li>Due o pi\u00f9 recidive nei 2 anni precedenti, oppure\n<\/li>\n \t<li>Una recidiva e\/o almeno 1 lesione T1 con aumento di gadolinio (Gd+) nell&#8217;anno precedente lo screening.\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-85954e8 elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"85954e8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-109cf1c elementor-widget elementor-widget-text-editor\" data-id=\"109cf1c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Le valutazioni neurologiche sono state eseguite ogni per 12 settimane e i pazienti sono stati sottoposti a risonanza magnetica (RMN) alle settimane 12, 24, 48 e 96.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-166298e\" data-id=\"166298e\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-a6fb013 elementor-widget elementor-widget-image\" data-id=\"a6fb013\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"1106\" height=\"644\" src=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064203\/briumvi-study-design-graphic-2.png\" class=\"attachment-full size-full wp-image-28947\" alt=\"\" srcset=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064203\/briumvi-study-design-graphic-2.png 1106w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064203\/briumvi-study-design-graphic-2-300x175.png 300w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064203\/briumvi-study-design-graphic-2-1024x596.png 1024w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064203\/briumvi-study-design-graphic-2-768x447.png 768w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064203\/briumvi-study-design-graphic-2-600x349.png 600w\" sizes=\"(max-width: 1106px) 100vw, 1106px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-2d80042 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"2d80042\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-50a207f\" data-id=\"50a207f\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-72578ea elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"72578ea\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-6d5de72\" data-id=\"6d5de72\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-791d90f elementor-widget elementor-widget-text-editor\" data-id=\"791d90f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t1\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e1b818 elementor-widget elementor-widget-text-editor\" data-id=\"4e1b818\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<strong>Endpoint primario\n<\/strong>\nTasso di ricaduta annualizzato (ARR) a 96 settimane\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-4919ece elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"4919ece\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-ebe42c1\" data-id=\"ebe42c1\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-506acf1 elementor-widget elementor-widget-text-editor\" data-id=\"506acf1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t2\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-42afe64 elementor-widget elementor-widget-text-editor\" data-id=\"42afe64\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Endpoint secondari selezionati<br \/><\/strong><\/p><ul><li>Numero di lesioni T1 Gd+ alla settimana 96<\/li><li>Numero di nuove lesioni T2 iperintense o in aumento alla settimana 96<\/li><li>Tempo per la progressione confermata della disabilit\u00e0 (CDP) per a 12 settimane<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-ac3ad1f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"ac3ad1f\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-1698256\" data-id=\"1698256\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-8ef3e9d elementor-widget elementor-widget-text-editor\" data-id=\"8ef3e9d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>I pazienti analizzati in entrambi gli studi avevano caratteristiche demografiche simili al basale<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cd90319 elementor-widget elementor-widget-image\" data-id=\"cd90319\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"2560\" height=\"1123\" src=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064212\/briumvi-study-design-img-1-2-scaled-1.png\" class=\"attachment-full size-full wp-image-28948\" alt=\"\" srcset=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064212\/briumvi-study-design-img-1-2-scaled-1.png 2560w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064212\/briumvi-study-design-img-1-2-scaled-1-300x132.png 300w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064212\/briumvi-study-design-img-1-2-scaled-1-1024x449.png 1024w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064212\/briumvi-study-design-img-1-2-scaled-1-768x337.png 768w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064212\/briumvi-study-design-img-1-2-scaled-1-1536x674.png 1536w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064212\/briumvi-study-design-img-1-2-scaled-1-2048x898.png 2048w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064212\/briumvi-study-design-img-1-2-scaled-1-600x263.png 600w\" sizes=\"(max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0cec4da elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-text-editor\" data-id=\"0cec4da\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t&nbsp;\n\n<style>\n    .reference-list {<br \/>      display: flex;<br \/>      flex-direction: column;<br \/>      gap: 1em;<br \/>    }<\/p>\n<p>    .reference-item {<br \/>      display: flex;<br \/>      align-items: flex-start;<br \/>    }<\/p>\n<p>    .reference-number {<br \/>      font-size: smaller;<br \/>      margin-right: 5px;<br \/>      vertical-align: super;<br \/>    }<\/p>\n<p>    .reference-text {<br \/>      text-align: left; \/* Alineaci\u00f3n a la izquierda *\/<br \/>    }<br \/>  <\/style>\n\n&nbsp;\n<div class=\"reference-list\">\n<div class=\"reference-item\">\n\n<strong>Notes<\/strong><br>\n<span class=\"reference-text\"><sup>a<\/sup> I valori espressi come pi\u00f9\/meno (\u00b1) sono le medie \u00b1 DS. La popolazione modificata intent-to-treat (mITT) comprende tutti i soggetti della popolazione ITT che hanno ricevuto almeno una dose del farmaco in studio e che hanno avuto almeno una valutazione dell&#8217;efficacia basale e post-basale. EDSS = Scala di Disabilit\u00e0 Espansa; DMT = Terapia Modificante la Malattia; DS = Deviazione Standard <\/span>\n\n<\/div>\n<\/div>\n&nbsp;\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7df6b97 elementor-widget elementor-widget-text-editor\" data-id=\"7df6b97\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t&nbsp;\n\n<style>\n    .reference-list {<br \/>      display: flex;<br \/>      flex-direction: column;<br \/>      gap: 1em;<br \/>    }<\/p>\n<p>    .reference-item {<br \/>      display: flex;<br \/>      align-items: flex-start;<br \/>    }<\/p>\n<p>    .reference-number {<br \/>      font-size: smaller;<br \/>      margin-right: 5px;<br \/>      vertical-align: super;<br \/>    }<\/p>\n<p>    .reference-text {<br \/>      text-align: left; \/* Alineaci\u00f3n a la izquierda *\/<br \/>    }<br \/>  <\/style>\n\n&nbsp;\n<div class=\"reference-list\">\n<div class=\"reference-item\"><strong>Riferimenti<\/strong><br>\n<span class=\"reference-number\"><sup>1<\/sup><\/span>\n<span class=\"reference-text\">Briumvi\u00ae. RCP<\/span><\/div>\n<div class=\"reference-item\"><span class=\"reference-number\"><sup>2<\/sup><\/span>\n<span class=\"reference-text\">Steinman L, Fox E, Hartung H-P, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N\nEngl J Med. 2022; 387(8): 704-714.doi:10.1056\/NEJMoa2201904.\n<\/span><\/div>\n<div class=\"reference-item\"><span class=\"reference-number\"><sup>3<\/sup><\/span>\n<span class=\"reference-text\">Supplement to: Steinman L, Fox E, Hartung H-P, et al. Ublituximab versus teriflunomide in relapsing\nmultiple sclerosis. N Engl J Med 2022;387:704-14. DOI: 10.1056\/NEJMoa2201904\n<\/span><\/div>\n<div class=\"reference-item\"><span class=\"reference-number\"><sup>4<\/sup><\/span>\n<span class=\"reference-text\">Sun Y, Izadi S, Callahan M, et al. Antibody-receptor interactions mediate antibody-dependent cellular\ncytotoxicity. J Biol Chem. 2021; 297(1): 100826. doi:10.1016\/j.jbc.2021.100826.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7e998da elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7e998da\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[],&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-d51106f\" data-id=\"d51106f\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-24385e1 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"24385e1\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-3e39f7a\" data-id=\"3e39f7a\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2f1a853 elementor-align-center elementor-widget elementor-widget-button\" data-id=\"2f1a853\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064335\/riassunto-briumvi-september3rd2025-color-print-pages.pdf\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Consulta il riassunto delle caratteristiche del prodotto<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Home BRIUMVI\u00ae \u00e8 stato valutato in 2 studi clinici identici globali randomizzati ed di FASE3 Criteri di inclusione: Sclerosi multipla recidivante Punteggio EDSS (Expanded Disability Status Scale) 0-5,5 Due o pi\u00f9 recidive nei 2 anni precedenti, oppure Una recidiva e\/o almeno 1 lesione T1 con aumento di gadolinio (Gd+) nell&#8217;anno precedente lo screening. Le valutazioni [&hellip;]<\/p>\n","protected":false},"author":2493,"featured_media":0,"parent":27270,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-27294","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sclerosi Multipla: Disegno Studio BRIUMVI - Neuraxpharm Italia<\/title>\n<meta name=\"description\" content=\"Scopri il disegno dello studio di BRIUMVI\u00ae per la sclerosi multipla recidivante: efficacia provata e profilo di sicurezza. Scopri di pi\u00f9.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Disegno dello studio\" \/>\n<meta property=\"og:description\" content=\"Scopri il disegno dello studio di BRIUMVI\u00ae per la sclerosi multipla recidivante: efficacia provata e profilo di sicurezza. Scopri di pi\u00f9.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\/\" \/>\n<meta property=\"og:site_name\" content=\"Neuraxpharm Italia\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-06T06:44:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.neuraxpharm.com\/it\/wp-content\/uploads\/sites\/5\/2026\/05\/briumvi-study-design-graphic-2.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/disegno-dello-studio\\\/\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/disegno-dello-studio\\\/\",\"name\":\"Sclerosi Multipla: Disegno Studio BRIUMVI - Neuraxpharm Italia\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/disegno-dello-studio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/disegno-dello-studio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2026\\\/05\\\/briumvi-study-design-graphic-2.png\",\"datePublished\":\"2025-04-07T12:53:55+00:00\",\"dateModified\":\"2026-05-06T06:44:57+00:00\",\"description\":\"Scopri il disegno dello studio di BRIUMVI\u00ae per la sclerosi multipla recidivante: efficacia provata e profilo di sicurezza. Scopri di pi\u00f9.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/disegno-dello-studio\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/disegno-dello-studio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/disegno-dello-studio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/static.neuraxpharm.com\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2026\\\/05\\\/06064203\\\/briumvi-study-design-graphic-2.png\",\"contentUrl\":\"https:\\\/\\\/static.neuraxpharm.com\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2026\\\/05\\\/06064203\\\/briumvi-study-design-graphic-2.png\",\"width\":1106,\"height\":644},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/disegno-dello-studio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Sclerosi multipla Briumvi\",\"item\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Disegno dello studio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/\",\"name\":\"Neuraxpharm Italia\",\"description\":\"A European Leader for the CNS products\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sclerosi Multipla: Disegno Studio BRIUMVI - Neuraxpharm Italia","description":"Scopri il disegno dello studio di BRIUMVI\u00ae per la sclerosi multipla recidivante: efficacia provata e profilo di sicurezza. Scopri di pi\u00f9.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio","og_locale":"it_IT","og_type":"article","og_title":"Disegno dello studio","og_description":"Scopri il disegno dello studio di BRIUMVI\u00ae per la sclerosi multipla recidivante: efficacia provata e profilo di sicurezza. Scopri di pi\u00f9.","og_url":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\/","og_site_name":"Neuraxpharm Italia","article_modified_time":"2026-05-06T06:44:57+00:00","og_image":[{"url":"https:\/\/www.neuraxpharm.com\/it\/wp-content\/uploads\/sites\/5\/2026\/05\/briumvi-study-design-graphic-2.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Tempo di lettura stimato":"2 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\/","url":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\/","name":"Sclerosi Multipla: Disegno Studio BRIUMVI - Neuraxpharm Italia","isPartOf":{"@id":"https:\/\/www.neuraxpharm.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\/#primaryimage"},"image":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.neuraxpharm.com\/it\/wp-content\/uploads\/sites\/5\/2026\/05\/briumvi-study-design-graphic-2.png","datePublished":"2025-04-07T12:53:55+00:00","dateModified":"2026-05-06T06:44:57+00:00","description":"Scopri il disegno dello studio di BRIUMVI\u00ae per la sclerosi multipla recidivante: efficacia provata e profilo di sicurezza. Scopri di pi\u00f9.","breadcrumb":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\/#primaryimage","url":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064203\/briumvi-study-design-graphic-2.png","contentUrl":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06064203\/briumvi-study-design-graphic-2.png","width":1106,"height":644},{"@type":"BreadcrumbList","@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/disegno-dello-studio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Sclerosi multipla Briumvi","item":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/"},{"@type":"ListItem","position":2,"name":"Disegno dello studio"}]},{"@type":"WebSite","@id":"https:\/\/www.neuraxpharm.com\/it\/#website","url":"https:\/\/www.neuraxpharm.com\/it\/","name":"Neuraxpharm Italia","description":"A European Leader for the CNS products","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuraxpharm.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/users\/2493"}],"replies":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/comments?post=27294"}],"version-history":[{"count":7,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27294\/revisions"}],"predecessor-version":[{"id":28955,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27294\/revisions\/28955"}],"up":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27270"}],"wp:attachment":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/media?parent=27294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}